Kiromic BioPharma Reports Favorable Results at Six Weeks from Fourth Patient in Deltacel-01 Clinical Trial

Scans of this first patient in the second cohort show 8.5% reduction in tumor size

...

Related Keywords

Beverly Hills ,Texas ,United States ,Houston ,Pietro Bersani ,Kiromic Biopharma ,Afshin Eli Gabayan ,Company Deltacel ,Beverly Hills Cancer Center ,Kiromic Biopharma Inc ,Twitter ,Linkedin ,Securities Exchange ,Gamma Deltat Cell ,Medical Oncologist ,Medical Director ,Principal Investigator ,Chief Executive Officer ,Gamma Deltat Cell Infusions ,Subjects With Stage ,Non Small Cell Lung ,Hills Cancer Center ,Gamma Deltat Cells ,Securities Exchange Act ,Annual Report ,